Claims circulating online assert that a nasal inhaler, marketed as “ReMind,” can reverse dementia, with endorsements from several high-profile celebrities. These assertions, however, have been debunked as entirely false. The product lacks regulatory approval and there is no scientific evidence supporting the notion that any medication can reverse dementia.
A number of advertisements on Facebook have promoted this product as a “new scientific breakthrough.” One ad boldly states, “Rejuvenate your brain and boost your memory by up to 94% – in just weeks.” Another asks, “Can you slow down Alzheimer’s?” Such claims have gained significant traction, particularly in Papua New Guinea.
The Facebook ads direct users to a website that features a supposed testimonial from a Dr. Henry Arthur, who claims to have developed the product. He describes it as “a true medical miracle” that has “completely revolutionized the dementia market in London.” However, investigations reveal that the website relies on misleading information, including fabricated endorsements and nonexistent medical experts. A reverse image search indicates that the photo of “Dr. Henry Arthur” is a stock image, not a real person.
Celebrity endorsements prominently feature actors such as Kate Winslet, Helen Mirren, and Benedict Cumberbatch. Yet, there is no credible evidence to suggest that these individuals have made any statements regarding the product. For instance, the image attributed to Helen Mirren actually belongs to a French actress, Veronique Cloutier. Additionally, the site claims that Winslet’s mother, who passed away in 2017 from ovarian cancer, had benefited from ReMind, suggesting a false narrative that her mother suffered from Alzheimer’s disease.
The website also claims that British television presenter Ant McPartlin provided £3.5 million in research funding for ReMind, a statement that lacks legitimate verification.
The product’s supposed “key ingredients” include ginkgo biloba, monk fruit extract, lavender, rosemary, and mint. While Dementia UK typically refrains from commenting on third-party advertisements, it advises on its website regarding approved medications for Alzheimer’s disease. The ingredients listed on the ReMind website are not recognized as effective treatments for dementia.
Research into ginkgo biloba has shown no beneficial effects on Alzheimer’s disease progression. A 2012 clinical trial published in The Lancet concluded that it did not provide any significant benefits. Similarly, a randomized trial involving 3,000 participants, published in the Journal of American Medicine in 2009, also found no positive impact. Alzheimer’s Research UK has stated that ginkgo biloba cannot be recommended for treatment or prevention of Alzheimer’s disease.
Moreover, the product “ReMind” has not been listed as an approved medication by either the Australian Register of Therapeutic Goods or the UK’s Medicine & Healthcare products Regulatory Agency. The advertisements make sweeping claims about ReMind’s abilities, asserting it can “reverse” dementia. However, as noted by the British Alzheimer’s Society, while some medications may provide temporary memory assistance, no products have been proven to slow or reverse dementia progression.
Additionally, claims that ReMind can “prevent” Alzheimer’s disease are misleading. Currently, there is no scientifically validated method to prevent the condition, as reiterated by Alzheimers.gov, the NHS, and Alzheimer’s Research Australia.
This situation underscores the importance of verifying health claims, especially those that exploit the concerns surrounding dementia and other neurodegenerative diseases. The proliferation of misinformation can have serious consequences for vulnerable individuals seeking legitimate treatments.
AAP FactCheck is an accredited member of the International Fact-Checking Network, committed to providing thorough research and accurate information. For ongoing updates on fact checks, follow AAP on various social media platforms.
